Who Generates More Revenue? Walgreens Boots Alliance, Inc. or Ionis Pharmaceuticals, Inc.

Walgreens vs. Ionis: A Revenue Battle from 2014 to 2023

__timestampIonis Pharmaceuticals, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 201421416100076392000000
Thursday, January 1, 2015283703000103444000000
Friday, January 1, 2016346620000117351000000
Sunday, January 1, 2017507666000118214000000
Monday, January 1, 2018599674000131537000000
Tuesday, January 1, 20191123000000120074000000
Wednesday, January 1, 2020729000000121982000000
Friday, January 1, 2021810000000132509000000
Saturday, January 1, 2022587000000132703000000
Sunday, January 1, 2023787647000139081000000
Monday, January 1, 2024705138000147658000000
Loading chart...

Igniting the spark of knowledge

Revenue Showdown: Walgreens Boots Alliance vs. Ionis Pharmaceuticals

In the ever-evolving landscape of the pharmaceutical and retail sectors, revenue generation is a key indicator of success. From 2014 to 2023, Walgreens Boots Alliance, Inc. has consistently outperformed Ionis Pharmaceuticals, Inc. in terms of revenue. Walgreens, a retail giant, has seen its revenue grow by approximately 82% over this period, peaking at an impressive $139 billion in 2023. In contrast, Ionis Pharmaceuticals, a leader in RNA-targeted drug discovery, experienced a more modest growth of around 268%, reaching nearly $788 million in 2023.

This stark contrast highlights the different scales and business models of these companies. While Walgreens benefits from a vast retail network, Ionis focuses on niche pharmaceutical innovations. The data also reveals a missing value for Ionis in 2024, suggesting potential challenges or strategic shifts. As the market continues to evolve, these companies' revenue trajectories will be crucial to watch.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025